Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,494.14 -7.51 -0.05%
S&P 500 1,878.34 2.95 0.16%
NASDAQ 4,137.82 10.85 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,171.08 -4.89 -0.15%
FTSE 100 6,684.33 9.59 0.14%
DAX 9,483.95 -60.24 -0.63%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Leadership Changes, New Studies, Acquisitions, New Care Facilities, and Business Transformations - Research Report on Cigna,



   Leadership Changes, New Studies, Acquisitions, New Care Facilities, and
   Business Transformations - Research Report on Cigna, HeartWare, Acadia,
                          Magellan, and Haemonetics

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 25, 2013

NEW YORK, June 25, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting CIGNA
Corporation (NYSE: CI), HeartWare International Inc. (NASDAQ: HTWR), Acadia
Healthcare Company Inc. (NASDAQ: ACHC), Magellan Health Services Inc. (NASDAQ:
MGLN), and Haemonetics Corporation (NYSE: HAE). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

CIGNA Corporation Research Report

On June 20, 2013, CIGNA Corporation (Cigna) announced the promotion of Peter
McCauley, M.D., to the position of Regional Medical Executive for the
Company's Northeast region, an area that includes 25 states in New England,
the Northeast, the Midwest and plains states, and Maryland, Virginia, and
Washington, D.C. In this position, he will oversee a team of five market
medical executives and 13 clinical program consultants. Cigna's market medical
executives and clinical program consultants help employer clients develop
health benefit plans and they also work with physician groups and hospital
systems to implement Cigna programs. The Company stated that McCauley will
continue to retain his current position as market medical executive for the
Midwest. The Full Research Report on CIGNA Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/700b_CI]

--

HeartWare International Inc. Research Report

On June 17, 2013, HeartWare International Inc. (HeartWare) announced that the
US Food and Drug Administration (FDA) has granted conditional approval to an
IDE (Investigational Device Exemption) supplement that allows the Company to
commence enrollment in an additional patient cohort for ENDURANCE, the
Company's pivotal clinical study to evaluate the use of HeartWare Ventricular
Assist System as a Destination Therapy in advanced heart failure patients. The
Company stated that in this supplemental cohort, the Company will enroll up to
an additional 240 HeartWare HVAD patients, as well as up to an additional 120
control patients using a randomization scheme consistent with the ENDURANCE
protocol. The patients will be studied for 12 months after the implant, and
the Company intends to include the data from this new cohort into an
anticipated Pre-Market Approval (PMA) Application seeking approval of the
HeartWare System for the Destination Therapy indication. The Full Research
Report on HeartWare International Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/086c_HTWR]

--

Acadia Healthcare Company Inc. Research Report

On June 20, 2013, Acadia Healthcare Company Inc. (Acadia) announced that it
has signed a definitive agreement to purchase The Refuge, a Healing Place, an
85-bed inpatient psychiatric facility near Ocala, Florida. The Company
reported that the psychiatric facility produced revenues of approximately $10
million in 2012. Joey Jacobs, Chairman and Chief Executive Officer of Acadia,
said, "We are pleased with our agreement to purchase this high quality
specialty inpatient psychiatric facility, which is the second transaction we
have announced in Florida in 2013. Consistent with our ongoing acquisition
strategy, we expect this transaction to be accretive to our financial results
and to represent a long-term growth opportunity for Acadia." The transaction
is expected to be completed during Q3 2013, subject to customary closing
conditions. The Full Research Report on Acadia Healthcare Company Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/c950_ACHC]

--

Magellan Health Services Inc. Research Report

On June 12, 2013 Magellan Health Services Inc. (Magellan) announced the launch
of Magellan Complete Care in Florida, a new Medicaid HMO health plan,
initially serving Broward County. According to the Company, Magellan Complete
Care helps those who are most challenged to navigate the health care system,
and provides the necessary support for members to improve their access to care
and quality of life. Through the Company's Care Coordination Team, Magellan
Complete Care reportedly manages mental and physical healthcare for all its
members. Scott R. Markovich, President of Magellan Complete Care, said, "We
see great opportunities to leverage Magellan's significant resources and
create an entirely new integrated care offering to help states grappling with
how to provide quality health care at affordable costs." The Full Research
Report on Magellan Health Services Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/4d84_MGLN]

--

Haemonetics Corporation Research Report

On June 19, 2013, Haemonetics Corporation (Haemonetics) announced several
developments in the pursuit of its previously announced manufacturing
transformation. First, the Company stated that Haemonetics has selected
Sanmina Corporation for the future production of medical devices currently
manufactured in Braintree, Massachusetts. Second, a location in Penang,
Malaysia, has been selected for the Company's Asian manufacturing facility.
Haemonetics stated that this location offers it proximity to customers in its
fastest growing markets and to a number of key suppliers and medical equipment
manufacturers, including Sanmina Corporation facilities. Third, the Company
announced plans to cease production operations at its manufacturing facility
in Ascoli-Pisceno, Italy, during the current fiscal year 2014. Production of
whole blood disposable sets, currently produced in Ascoli-Piceno, will be
transferred to the Company's manufacturing facilities in Tijuana, Mexico and
Covina, California. The Full Research Report on Haemonetics Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/7366_HAE]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America) RW:
adam.redford@portsourceltd.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement